Prostate specific antigen (PSA) is the most commonly used biomarker for PCa screening; however, routine PSA screening has a USPSTF rating of C for men 50–69 and D for men 70+, indicating an unclear benefit [3]. The gene discussed is KLK3; the disease is posterior cortical atrophy.